Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439609 | 0.89 | PDE4B (0.45) | PDE4BJAK2 | |
| SCHEMBL17439532 | 0.87 | PDE4B (0.56) | PDE4B | |
| SCHEMBL17439508 | 0.87 | PDE4B (0.49) | PDE4BALKMKNK1MKNK2EGLN1 | |
| SCHEMBL17439578 | 0.87 | PDE4B (0.48) | PDE4BLRRK2 | |
| SCHEMBL17439507 | 0.86 | PDE4B (0.50) | PDE4BALKMKNK1MKNK2EGLN1 | |
| SCHEMBL17443587 | 0.85 | PDE4B (0.51) | PDE4BALKMKNK1MKNK2EGLN1 | |
| SCHEMBL17439516 | 0.81 | PDE4B (0.47) | PDE4BJAK2 | |
| SCHEMBL17439538 | 0.80 | GLA (0.42) | PDE4BLRRK2JAK2 | |
| SCHEMBL17439515 | 0.80 | PDE4B (0.44) | PDE4B | |
| SCHEMBL17443932 | 0.79 | PDE4B (0.51) | PDE4BALKMKNK1MKNK2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| EP-3415510-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008590-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885ALK 3833/4885MKNK1 4281/4885 |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885ALK 3833/4885MKNK1 4281/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885ALK 3901/4885MKNK1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.